For those chronic hepatitis C patients, who are interferon-ineligible or intolerant, there is a burning need for the development of pan-oral interferon-free regimen. The investigators examine the efficacy and safety of sofosbuvir, a NS5B nucleotide polymerase inhibitor and daclatasvir, an NS5A replication complex inhibitor in Chinese treatment-experienced cirrhosis patients with chronic G1b infection.
Name: SofosbuvirDescription: Sofosbuvir 400 mg tablet administered once dailyType: Drug
Name: DaclatasvirDescription: Daclatasvir 60mg tablet administered once dailyType: Drug
Description: SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) (15 IU/ml) 12 weeks following the last dose of study drugMeasure: Proportion of participants with sustained virologic response 12 weeks after the end of treatment (SVR12) Time: Post treatment Week 12
Single Group Assignment
There is one SNP
At baseline, liver stiffness measurement (LSM) using transient elastography (FibroScan®) is used to assess liver fibrosis and the single nucleotide polymorphism ofinterferon-λ 3 (IL-28, rs12979860, C or T) and IFLN4 (ss469415590, TT or ΔG) is determined.